InstructorRoyed Training
TypeOnline Course
Student Enrolled1
Price$490 / 27500 INR.
Buy NowBook Now
Loading
Loading
heor training course

Introduction

Features

Features

Related Courses

Course Content

heor online training

This online HEOR training course focuses on how healthcare decision makers compare and choose among the available therapeutic options. The course provides orientation to practical understanding in the pharmaco-economic evaluations. Learn how to manage each step of the Pharmacoeconomics carried out effectively. Further, the course provides extensive training on pharmacoeconomic modeling which is key for healthcare decision making. Fourthly, training includes exclusive hands-on training on real life evidence (RWE). Lastly, this online training helps you to understand the practical simulation on calculation of the QALY, ICER, WTP, ATP, Discounting, etc. which are key for analyzing the pharmacoeconomic outcome.

This HEOR training course is designed to challenge students to apply what they have learned through the use of interactive exercises, reflection questions. Hence this training provides real life requirement for drug development and commercialization.

The course can be completed at any pace, allowing the user to stop and start at their leisure.

  • Course Code: RYD-108
  • Course Title: Advanced Certification in Health Economics Outcomes Research (HEOR)
  • Types of Learning: Online Self Paced Learning
  • Duration: 1 Month
  • Course Certificate: Course certificate will be issued at the end of the course.

1 Year Executive Program in Pharma Global Management course covers HEOR topics along with the other important strategic management topics.

Course features

  • Orientation to job related practical aspects for the HEOR professionals.
  • Course provides simulation to real life working in HEOR department. Hence, it help to enhance the HEOR decision making process.
  • Moreover course provides hands on training on pharmacoeconomic modeling. How the pharmacoeconomic calculations are carried out.
  • Above all, the course provides access to Case Studies to learn about the HEOR.

Who should attend this course? 

  • Those who are in working in drug discovery and development, and working on the commercialization of the pharmaceuticals.
  • Professionals working in health care settings including payer organizations, health insurance industry, government, the life sciences, pharmaceutical and biomedical industries.
  • Health care providers interested in health economics and outcomes research.
  • Professionals working within Health Technology Assessment or reimbursement organizations and other areas where allocation of resources and decisions for coverage and access are relevant.
  • Fresher or beginners, Those who want to make a career in pharmacoeconomic or in HEOR department.

Key Topics covered in the HEOR training course 

The course is broken down into various lecture sessions:

  • Introduction to Health Economics | Key terminologies related to health economics.
  • HEOR Application in Pharmaceutical and Biopharmaceutical Industry.
  • Introduction to Pharmacoeconomics | Different Types of Economic Evaluation | Cost-effectiveness plane | Economic modeling |Sensitivity Analysis | One way sensitivity analysis | Probabilistic sensitivity analysis.
  • Economic Evaluation Methods | Various methods | Importance of perspective in health economics | Discounting | Uncertainty.
  • Core fundamentals of Health Economics | Clinical and economic burden | Public Health Care Payer Vs. Patient and Societal | Positioning a new treatment with the current treatment | QALY | ICER | Threshold value | Clinical trials vs health economics assessment.
  • Pharmacoeconomic Evaluation Checklist | Health Economics Map | Economic evaluation cycle | Checklist of economic evaluation | Costs and Outcome relevant to different groups | Comparators | Problem of choosing the comparators.
  • Pharmacoeconomic Evaluation – Resource and Cost | Fixed, Variable and Total Cost | Calculation | Average vs. marginal cost | Importance of marginal cost | Discounting | Discounting calculation | Preferable discounting rate | Sources of unit cost data | Reference costs.
  • Pharmacoeconomic Evaluation – Benefits and Outcome | C/E Ratio | Intermediate Vs. Final Outcome | Sources of Effectiveness Data | QALY | Utility Weight | WTP | VPF | ATP | Difference between WTP & ATP.
  • CER and PCOR.
  • Evidence Based Decision Making | Real World Evidence
Section 1Introductory Sessions
Lecture 1Introduction to Health Economics | Key terminologies related to health economics
Lecture 2HEOR Application in Pharmaceutical and Biopharmaceutical Industry
Section 2Pharmacoeconomic Evaluation
Lecture 3Introduction to Pharmacoeconomics | Different Types of Economic Evaluation | Cost-effectiveness plane | Economic modeling |Sensitivity Analysis | One way sensitivity analysis | Probabilistic sensitivity analysis 
Lecture 4Economic Evaluation Methods | Various methods | Importance of perspective in health economics | Discounting | Uncertainty 
Lecture 5Core fundamentals of Health Economics | Clinical and economic burden | Public Health Care Payer Vs. Patient and Societal | Positioning a new treatment with the current treatment | QALY | ICER | Threshold value | Clinical trials vs health economics assessment
Lecture 6QALY | How to calculate QALY | Importance and Significance 
Lecture 7ICER | How to calculate ICER | Importance and Significance | Incremental Effectiveness determination 
Lecture 8Pharmacoeconomic Evaluation Checklist | Health Economics Map | Economic evaluation cycle | Checklist of economic evaluation | Costs and Outcome relevant to different groups | Comparators | Problem of choosing the comparators
Lecture 9Pharmacoeconomic Evaluation - Resource and Cost | Fixed, Variable and Total Cost | Calculation | Average vs. marginal cost | Importance of marginal cost | Discounting | Discounting calculation | Preferable discounting rate | Sources of unit cost data | Reference costs
Lecture 10Pharmacoeconomic Evaluation - Benefits and Outcome | C/E Ratio | Intermediate Vs. Final Outcome | Sources of Effectiveness Data | QALY | Utility Weight | WTP | VPF | ATP | Difference between WTP & ATP 
Lecture 11Pharmaco-economic evaluation – analysis and results | Different Types of Models | Understanding Decision Tree - Components with practical Example | Markov model 
Lecture 12CER and PCOR
Lecture 13Budget Impact Analysis | Importance | Significance | Steps involved | Total Budget Impact Calculation | Simulation - BIA of novel molecule with real life example | Total Budget Impact Calculation for Novel Molecule 
Lecture 14Markov Model | Significance | Importance | Time horizon - Significance | Real Life Development of Markov Model | Calculation 
Section 3Evidence Based Decision Making
Lecture 15Evidence Based Decision Making | Combine evidences for decision making | Do we need more evidence? 
Lecture 16RWE and RWD
Lecture 17RWE in lifescycle management
Lecture 18RWD and RWE - Fit to use | Assessment 
Lecture 19RWD data sources | Different types | Detailed understanding of each class 
Lecture 20RWE - Study Design
Lecture 21RWE - Published Tool
Lecture 22RWD Study Design
Lecture 23Healthcare Reimbursement Models : Value Based Care | Fee for Service (FFS) Model | Other Reimbursement Models
Lecture 24HEOR Consensus Narrative Review 
Lecture 25Electronic Patient Data | EMR | EHR | Differences | Software architecture and characteristics
Lecture 26Active Surveillance Schemes | Active Case Finding |Sentinel Surveillance | Cohort Studies | Vaccine Safety Surveillance | Pharmacovigilance Programs | Disease Registries |Event Monitoring
Section 4Costing, Pricing and Reimbursement
Lecture 27Overlapping HEOR and Market Access | Market Access Strategic Planning : Steps and Logical Sequencing for Market Access Strategy Development
Lecture 28Indication Sequencing | Indication Prioritization | Development of Indication Timeline | Indication Matrix | Value Based Indication Prioritization
Lecture 29Indication Prioritization Case Study
Lecture 30Value Dossier : What it is | Significance | Components | What to include
Lecture 31AMCP Market Access Dossier Preparation 
Lecture 32Drug Pricing Methodologies I
Lecture 33Drug Pricing Methodologies II
Lecture 34Formulary Placement | Different Tiers | How to classify the medication in different tiers | Formulary negotiation process | Rebates | Copay differential | Step-edits | Case Simulations - teasers
Lecture 35Pricing Case Study
Lecture 36Budget Impact Analysis
Lecture 37Healthcare Reimbursement Models : Value Based Care | Fee for Service (FFS) Model | Other Reimbursement Models
Lecture 38Rebates | Importance | Factors affecting Rebates | Deductibles and Rebates
Lecture 39Medicare | Medicaid | Medigap | Different plans | Related Terminologies| Advanced training on Medicare Part D
Lecture 40Practical Training on Value Dossier Preparation | Sample Value Dossier with each section with data | Key points to consider while preparing value dossier 
Lecture 41Clinical Data in Value Dossier | Understanding in different types of clinical study with rationale | Case based example on clinical study section writing
Section 5Discussion | Queries | Reference Learnings
Lecture 42HEOR & New Drug Market Launch
Lecture 43Economic and humanistic burden of the disease
Lecture 44Policy implications of the study findings
Lecture 45Potential barriers to the widespread adoption of the intervention
Lecture 46What are the long-term effects of the intervention on patient health and healthcare costs?
Lecture 47HEOR review test 
Section 6Course Certification